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Abstract 
 
WATERMELON SUPPLEMENTATION TO IMPROVE SYSTEMIC 
ATHEROSCLEROTIC RISK FACTOR BIOMARKERS IN OVERWEIGHT POST-
MENOPAUSAL WOMEN IN A COMMUNITY SETTING 
 
Lauren Carson 
B.S., Appalachian State University 
M.A., Appalachian State University 
 
 
Chairperson: R. Andrew Shanely 
 
 
 The purpose of this study was to determine the degree to which six select markers of 
atherosclerotic risk were affected by a six-week watermelon consumption intervention in 
overweight post-menopausal women in a community setting. METHODS: Forty five subjects 
met the criteria and completed the pre- and post- study visit after an overnight fast. Height, 
weight, percentage of body fat, and a blood sample were taken during both visits.  During the 
pre-study visit, the subjects were randomly assigned to either the control (no intervention) 
group or the watermelon treatment group.  The watermelon group consumed 710 mL (1.88 
grams of L-citrulline/ 0.39 grams of L-arginine) of watermelon puree per day for the six-
week period. The plasma concentration of sVCAM-1, ADAMTS 13, GDF-15, sICAM-1, and 
sP-selectin were measured pre- and post-treatment period. RESULTS: There was a 
significant (p = 0.005) 8.4% increase in the plasma concentration of L-arginine that occurred 
in the watermelon group between the pre- and post-treatment period. Also, there was a 
significant decrease (p = 0.003) in plasma VCAM-1 concentrations that occurred in the 
 v 
watermelon group between the pre- and post-treatment. The pattern of change in the plasma 
concentration of sICAM-1, ADAMTS 13, GDF-15, sP-selectin, and L-citrulline did not 
differ between treatment groups (all, p >0.05). The plasma concentration of fibrinogen was 
above detection limits and therefore, not included in the statistical analysis. CONCLUSION: 
The six-week watermelon supplementation treatment resulted in a small but significant 
increase in VCAM-1, but no changes in the other atherosclerotic biomarkers measured. 
Additional studies are needed to determine if a longer treatment period and/or greater dose of 
watermelon puree is required to decrease atherosclerotic risk in overweight post-menopausal 
women in a community setting.   
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Introduction 
Cardiovascular diseases (CVDs) are the leading cause of death worldwide (50, 65). 
Menopause, an absence of a menstrual period for one year due to aging, increases a woman’s 
risks for developing CVDs, specifically atherosclerosis, due to estrogen depletion. 
Furthermore, menopause increases the risk for oxidative stress (2), which can increase the 
risk for hypertension and arterial stiffness (20, 58). Estrogen plays a protective role in a 
woman’s body by increasing vasodilation through nitric oxide (NO) via endothelium nitric 
oxide synthase (eNOS) (57). This indirectly protects women from oxidative stress and is 
done through a receptor mediated system where estrogen binds to the estrogen receptor ERα. 
During menopause, there is a decrease in circulating estrogen levels (38, 58). This decrease 
in estrogen levels leaves post-menopausal women more at risk for developing oxidative 
stress and endothelial dysfunction, increasing their risk for atherosclerosis (32). 
Atherosclerosis is the buildup and hardening of plaque on the artery walls, which 
narrows the cross-sectional area of arteries and consequently decreases blood flow. 
Atherosclerosis is caused by an increase in oxidative stress and decrease in NO 
bioavailability leading to endothelial dysfunction (32). Early stages of atherosclerosis include 
recruitment and buildup of leukocytes mediated by cellular adhesion molecules causing 
inflammation of the arteries (7).  This ultimately leads to a cascade effect causing an increase 
in endothelial dysfunction, vasoconstriction, and risks for other CVDs.  
NO is a reactive molecule that plays an important role in healthy vascular 
maintenance and vasodilation. There are three nitric oxide synthase (NOS) isoforms that 
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produce NO. However, eNOS isoform derived NO production results in vasodilation and 
decreases atherosclerosis risk factors by decreasing platelet activation and platelet adhesion 
to the endothelium (32). NO production occurs via eNOS, cofactors for eNOS, and the 
citrulline-NO cycle (24). Oral consumption of L-citrulline and L-arginine modulate NO 
production (23).  
 Watermelon is high in free water, has many nutrients, and may decrease overweight 
post-menopausal women’s risk for atherosclerosis. Consumption of watermelon, a rich 
source of L-citrulline and L-arginine (54), can increase plasma L-citrulline and L-arginine 
(13, 47) and allow L-citrulline and L-arginine to be readily available for NO production (13). 
The extracellular availability of L-arginine is a rate-limiting factor in NO production (24). 
The citrulline-NO cycle plays a more important role in the production of L-arginine for NO 
production compared to oral supplementation of L-arginine (24). However, oral 
supplementation of L-arginine and L-citrulline helps in NO production via eNOS (23).   
 Bloodborne biomarkers can be used to gauge the inflammatory response that leads to 
atherosclerosis. Circulating levels of inflammatory proteins including soluble vascular cell 
adhesion molecule-1 (sVCAM-1) (5), soluble intercellular adhesion molecule-1 (sICAM-1) 
(5), soluble P-selectin (sP-selectin) (5), fibrinogen (5), and growth differentiation factor-15  
(GDF-15) (41) increase when atherosclerotic risk factors increase (5, 41).  ADAM 
metallopeptidase with thrombospondin type 1 motif, 13 (ADAMTS 13) circulatory levels 
decrease as the risk of atherosclerosis risk increases (8). Each biomarker has a different affect 
in the body; however, each can be used to gauge the amount of inflammation due to 
endothelial damage.  
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Previous research has demonstrated the efficacy of daily watermelon consumption to 
increase the bioavailability of L-citrulline and L-arginine to increase fasting plasma levels of 
L-arginine (13) thus increasing NO via eNOS. This can enhance in vitro NO-dependent 
aortic ring vasoreactivity (66) and may decrease inflammation associated with the risk for 
atherosclerosis. Previous research has also demonstrated that the selected inflammation 
biomarkers can be used to gauge a person’s risk for atherosclerosis (5, 8, 41).  This study 
tested the hypothesis that sICAM-1, sVCAM-1, sP-selectin, GDF-15, and fibrinogen plasma 
concentrations will decrease, and ADAMTS 13 plasma concentrations will increase after six 
weeks of watermelon supplementation in overweight post-menopausal women. Therefore, 
the purpose of this study was to determine the degree to which six select markers of 
atherosclerotic risk were affected by the six week watermelon consumption intervention in 
overweight post-menopausal women in a community setting.  
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Literature Review 
 Cardiovascular diseases (CVDs), specifically atherosclerosis, pose a serious problem 
for overweight post-menopausal women (20, 29, 58, 62). There are many risk factors for 
CVD that increase when a woman becomes post-menopausal, but some risk factors can be 
diminished (59, 68). Watermelon supplementation may decrease CVD risk factors by 
increasing plasma L-arginine and L-citrulline levels, which can lead to the production of 
nitric oxide (NO) (13, 23, 47).  
Previous research has demonstrated the efficacy of daily watermelon consumption to 
increase the plasma levels of L-arginine and L-citrulline (13, 47). In Zucker diabetic fatty 
(ZDF) rats, watermelon pomace juice supplementation increases tetrahydrobiopterin (BH4) 
synthesis and bioavailability by increasing GTP cyclohydrolase-1 activity (the first and rate 
limiting enzyme in the de novo production of BH4) while increasing endothelium nitric 
oxide synthase (eNOS) activity and NO production (66). Increased circulating NO enhances 
vasodilation and may decrease inflammation associated with the risk for CVD. Previous 
research has also demonstrated that the selected inflammation biomarkers can be used to 
gauge a person’s risk for atherosclerosis (5, 8, 41). This study tested the hypothesis that 
sICAM-1, sVCAM-1, sP-selectin, GDF-15, and fibrinogen plasma concentrations will 
decrease, and ADAMTS 13 plasma concentrations will increase after six weeks of 
watermelon supplementation in overweight post-menopausal women.  Therefore, the purpose 
of this study was to determine the degree to which six select markers of atherosclerotic risk 
were affected by the six week watermelon consumption intervention in overweight post-
menopausal women in a community setting. 
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Cardiovascular Disease and Post-Menopausal Women 
 Cardiovascular diseases affect the heart and blood vessels and are the leading cause 
of death worldwide (50, 65). Cardiovascular diseases have many modifiable and non-
modifiable risk factors. Non-modifiable risk factors that cannot be prevented include 
heredity, sex, ethnicity, and age; while modifiable risk factors include hypertension, high 
cholesterol, obesity, smoking and a sedentary lifestyle (21, 22). These are also some of the 
main risk factors for developing atherosclerosis. 
Atherosclerosis is the buildup and hardening of plaque on the artery wall. This 
narrows the lumenal area of arteries and consequently decreases blood flow. Atherosclerosis 
is caused by an increase in oxidative stress and a decrease in NO bioavailability leading to 
endothelial dysfunction (32). Early stages of atherosclerosis includes a recruitment and 
buildup of leukocytes mediated by cellular adhesion molecules causing inflammation of the 
arteries (7).  This ultimately leads to a cascade effect causing an increase in vasoconstriction, 
endothelial dysfunction, and risks for other CVDs. 
 Menopause is an absence of a menstrual period for one year due to aging. It is 
unavoidable for aging women and is accompanied by many health and lifestyle changes. 
Menopause can increase a woman’s risk for hypertension and arterial stiffness (20), which 
can increase oxidative stress and endothelial dysfunction (2, 32). This is due to physical 
changes in hormone levels and lifestyle of women during the aging process.  During post-
menopause, there is a decrease in circulating estrogen and other sex hormone levels (38, 58). 
This is harmful for aging women, because estrogen plays a protective role in the woman’s 
body, and through estrogen depletion, there is a decrease in NO bioavailability leading to an 
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increased risk for multiple chronic diseases in women (38, 57). Specifically, the decrease in 
estrogen levels leaves post-menopausal women more at risk for oxidative stress and 
endothelial dysfunction increasing their risk for atherosclerosis (32). 
 Estrogen protects women from atherosclerosis while growth factors and cytokines 
play important roles in mediating atherosclerosis (37). Kamada et al. (37) examined fifteen 
cytokines from 97 post-menopausal women who were either receiving hormone replacement 
treatment or no treatment. It was concluded that hormone replacement therapy can increase 
the production of macrophage colony-stimulating factor, which can decrease serum 
cholesterol levels (37). This may prevent atherosclerosis and provides evidence that estrogen 
is a protective hormone for women.  
Estrogen can increase endothelial NO production through a receptor-mediated system 
and the estrogen receptor ERα (11, 31, 44, 57). Estrogen and ERα activate mitogen-activated 
protein (MAP) kinase and tyrosine kinase, which causes intracellular Ca
2+
  and NO to 
increase (11). This is important because estrogen can increase vasodilation and protect 
women from atherosclerosis. It has been observed in monkeys and rabbits that short-term and 
long-term estrogen therapy can improve endothelium-dependent vasodilation (44) through a 
protein kinase B (Akt)-dependent mechanism (35).  When women reach post-menopause, 
NO production decreases due to estrogen depletion; however, therapeutic strategies to 
increase endothelial NO production have been sought.   
L-Citrulline, L-Arginine, and Nitric Oxide Relationship 
Nitric oxide plays an important role in vasodilation and is a component of healthy 
vasculature maintenance. There are three isoforms of nitric oxide synthase (NOS). Two are 
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constitutively expressed (NOS1 or neuronal NOS and NOS3 or endothelial NOS) and the 
third is inducible (NOS2 or inducible NOS). eNOS is the isoform that is involved in the 
endothelium response activating vasodilation through the L-citrulline-NO cycle (24). eNOS 
is regulated and activated by Ca
2+
 and calmodulin (1, 25) and has cofactors including: BH4, 
nicotinamide adenine dinucleotide phosphate (NADPH), flavin mononucleotide/flavin 
adenine dinucleotide (FMN/FAD) (56). eNOS is also the NOS isoform that plays an 
important role in decreasing atherosclerosis risk. Atherosclerosis is increased when there is a 
dysfunction with endothelial cells, decreased bioavailability of L-arginine and cofactors, and 
decreased expression of eNOS (10, 32, 34). Endothelial cell dysfunction increases lesion 
formation (30). This increases inflammation and hypertrophy of smooth muscle cells, which 
contributes to blood clotting and vasoconstriction (6, 55).  A component of endothelial cell 
dysfunction is decreased bioavailability of L-arginine.  
L-arginine has the ability to reduce atherosclerosis risk factors including adipose 
tissue, hypertension, and aortic stiffness (23, 48, 66).  L-arginine is a cell signaling molecule 
to NO, glutamate, and agmatine (decarboxylated arginine) (67). Extracellular L-arginine is a 
rate-limiting factor in NO production; however, the majority of L-arginine availability is not 
utilized in NO production (24). While oral L-arginine supplementation can increase NO 
levels (23, 66), the L-citrulline-NO cycle plays a more important role in the production of L-
arginine for NO production (24).  
 L-citrulline is a non-essential amino acid that can be used in the synthesis of L-
arginine and thus NO (24, 54). Endogenous synthesis of L-arginine from L-citrulline occurs 
when L-citrulline is released by the small intestine into the blood stream where it is extracted 
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by the kidneys (67). L-citrulline is then converted into L-argininosuccinate through 
argininosuccinate synthase, then to L-arginine through argininosucinate lyase, and finally L-
arginine is converted to NO through eNOS and eNOS cofactors (24, 42, 49, 67). This is 
known as the citrulline-NO cycle (24, 67). Nitric oxide can also be increased by L-arginine 
through intracellular tetrahydrobioprterin (BH-4)-dependent NO synthase (33, 66). 
Watermelon and the L-Citrulline-Nitric Oxide Cycle 
 Consumption of watermelon, a rich source of L-citrulline and L-arginine (54), 
increases fasting plasma L-citrulline and L-arginine (13). Wu et al. (66) compared L-arginine 
availability during watermelon pomace juice supplementation (which included L-citrulline 
and L-arginine) in Zucker diabetic fatty (ZDF) rats. The ZDF rats were deficient in GTP 
cyclohydrolase-1, thus, impairing eNOS. GTP cyclohydrolase-1 is the rate-limiting enzyme 
for  BH4 synthesis (66). In ZDF rats, higher L-arginine concentrations increased GTP 
cyclohydrolase-1 activity, thus increasing the synthases and bioavailability of BH4 (66). Wu 
et al. (66) reported that GTP cyclohydrolase-1 activity increased 39% and BH4 
concentrations increased about 36% with watermelon pomace juice supplementation. 
Additionally, serum concentrations of L-arginine, nitrite and nitrate, and oxidation products 
of NO, were increased through watermelon supplementation (66). Wu et al. concluded that 
L-arginine synthesis occurred via L-citrulline and is then converted into NO via eNOS (66). 
This data supports the notion that L-citrulline can increase circulating L-arginine levels, and 
thus, increase the eNOS cofactor BH4 and NO production.  
  Collins et al. (13) compared the fasting plasma concentration of L-arginine and L-
citrulline through watermelon juice consumption in healthy adults. Twelve males and eleven 
9 
 
 
females, ages 36-69 years old, consumed one of three different amounts of watermelon juice 
for three-weeks each. The low watermelon condition consisted of three containers each day 
of 0.78kg of juice to deliver 1.025g of L-citrulline plus 0.228g of L-arginine per day. The 
high watermelon condition consisted of six containers each day of 1.56kg of juice to deliver 
2.051g of L-citrulline plus 0.455g of L-arginine per day. Meals were prepared by a registered 
dietitian to control L-citrulline and L-arginine intake and to maintain body mass throughout 
treatment. The authors concluded that fasting plasma L-arginine concentrations increased in 
the high (22%) and low (11%) watermelon groups during the three-week supplementation 
period, while fasting L-citrulline plasma concentrations had no significant changes. They 
concluded that L-citrulline is bioavailable and is converted into L-arginine, and thus 
increases plasma L-arginine levels (13).   
 Figueroa et al. (23) examined the effect of watermelon supplementation on aortic 
blood pressure, wave reflection, and pulse wave velocity on pre-hypertensive middle-aged 
individuals (ages ranging between 51-57 years). Four males and five females, who were all 
pre-hypertensive, were recruited for the study and randomly divided into two groups. Each 
group concluded the six-week watermelon supplementation intervention and the six-week 
placebo intervention with a four-week washout period in between interventions.  During the 
six-week watermelon supplementation period, subjects consumed 1.35g of L-citrulline and 
0.65g of L-arginine two times per day to deliver 2.7g of L-citrulline and 1.3g of L-arginine 
per day. An overnight fast was conducted before and after each intervention, and blood 
pressure, wave reflection, and pulse wave velocity were taken during each visit. The authors 
concluded that aortic blood pressure, wave reflection, and aortic and brachial pulse pressure 
decreased significantly after the six-week watermelon supplementation period. This study 
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indicates that a six-week watermelon intervention of L-citrulline and L-arginine can have 
beneficial effects on pulse pressure, which can decrease hypertension (a risk factor for 
atherosclerosis) (23).  
Biomarkers for Atherosclerotic Risk Factors 
Cell Adhesion Molecules  
Cell adhesion molecules (CAMs) are proteins on the cell surface that interact with 
ligands, which allow for cell to cell or cell to matrix interactions (39).  There are many 
different types of CAMs; some of which are linked to inflammation and immune responses 
(39). CAMs have been used as CVD and atherosclerosis biomarkers because, inflammation is 
related to atherosclerosis risk factors, and higher expressions of CAMs are associated with 
high endothelial inflammation (4, 43). Inflammation markers are significant predictors of 
CVD events and atherosclerosis in post-menopausal women (53). Soluble vascular cell 
adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), and 
soluble P-selectin (sP-selectin) are proteins of the endothelial cell surface that interact with 
extracellular matrix components to attract immune cells to damaged endothelial areas. 
Specifically, sP-selectin draws leukocytes from the circulation to the damaged endothelium 
by weakly binding to carbohydrate ligands on the surface of the leukocytes. The weak 
binding will cause the leukocyte to decelerate and roll across the endothelium surface, where 
sVCAM-1 and sICAM-1 create a strong attachment to the leukocyte and are involved with 
transendothelial migration (18, 36). While the effects of these selected CAMs are mainly on 
cell surfaces, their soluble forms found in plasma are indicative of their membrane bound 
expression levels (45). 
11 
 
 
Elevated sICAM-1 is an independent risk factor for myocardial infarction (18) and 
allows for leukocytes to form an adhesion to damaged or inflamed endothelium (51).  
sICAM-1 allows for leukocytes to form an adhesion to the endothelium through binding of 
leukocyte intergrins, leukocyte function associated antigen-1 (LFA-1) and Mac-1(51). Ridker 
et al. (53) examined 28,263 post-menopausal women’s plasma sICAM-1 levels over a three-
year time period. The data indicates that sICAM-1 was a significant predictor for adverse 
cardiovascular events, i.e., higher plasma levels of sICAM-1 are correlated with 
atherosclerosis risk factors and CVD events (53).  
 sVCAM-1 is a cell adhesion molecule that can have a weaker expression during CVD 
compared to other CAMs; however, sVCAM-1 has a higher expression during the early 
stages of atherogenesis (36). sVCAM-1 interacts with the very late antigen 4 to allow the 
activation and initiation of atherosclerosis (7). There is evidence that NO can limit the 
expression of sVCAM-1 (43); therefore, increases in NO may result in lower sVCAM-1 
expression.  
sP-selectin is a cell adhesion molecule involved with leukocyte attachment to 
damaged endothelium sites (9, 51). Carter et al. (9) compared the relationship of plasma sP-
selectin levels to coronary artery disease in 249 coronary artery patients and 252 healthy 
patients. sP-selectin levels were significantly higher in patients with higher cardiovascular 
risk factors and become more apparent when there are signs of atherosclerosis (9). 
A study conducted by Demerath et al. (18) compared the relationship of sICAM-1, 
sVCAM-1, sP-selectin, and E-selectin to CVD and atherosclerosis risk factors in 281 males 
and 311 females. Other CVD lifestyle risk factors were measured. The results indicated that 
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soluble adhesion molecule concentrations increase as CVD risk factors increase (18). This 
supports the use of measuring plasma levels of sVCAM-1, sICAM, and sP-selectin as 
biomarkers for atherosclerosis. 
ADAMTS 13  
ADAM metallopeptidase with thrombospondin type 1 motif, 13 (ADAMTS 13) is a 
metalloprotease that decreases inflammation during atherosclerosis by cleaving highly active 
Von Willebrand Factor (VWF) thus making less active VWF (8, 27). VWF proteins are 
glycoproteins that are part of the blood clotting cascade and are involved in the recruiting and 
adhesion of platelets to atherosclerotic sites (27). The ratio between ADAMTS 13 and VWF 
are significant predictors of CVD risks when there is a low ADAMTS 13 and high VWF:Ag, 
also ADAMTS 13 alone is significantly correlated to endothelial dysfunction (28).  
 ADAMTS 13 levels are lower and VWF levels are high in young individuals (<45 
years males, <55 years females) with higher risk of CVD than in subjects of the same age 
range with low risk of CVD (8).  Subjects with lower levels of ADAMTS 13 were five times 
more at risk for CVD than subjects with normal levels of ADAMTS 13 (8). This data 
supports the use of ADAMTS 13 as a marker of CVD risk.  
Growth Differentiation Factor – 15 
 Growth differentiation Factor – 15 (GDF-15) is a stress responsive cytokine used as a 
biomarker to identify endothelial dysfunction and cardiovascular dysfunction (41, 46). 
Increased levels of GDF-15 are linked to increased risk of CVD and atherosclerosis (64). 
GDF-15 is weakly expressed in healthy individuals; however, its expression increases 
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sharply during tissue injury or inflammation (46).  GDF-15 is not a cardiac specific cytokine, 
but it could affect other tissues that are injured or inflamed. However, in rats and humans 
GDF-15 expression is increased in the heart after a myocardial infarction as a defensive 
mechanism (40). GDF-15 expression is increased during oxidative stress, antiangiogenic 
stress, and in response to increased pro-inflammatory cytokines, increased oxidized low 
density lipoproteins, and mechanical stress (41); all risk factors for atherosclerosis. A 
decrease in GDF-15 suggests a decreased risk for CVD.  
Fibrinogen  
 Fibrinogen is a glycoprotein involved in the blood clotting cascade and is an 
independent risk factor for CVD (60). Fibrinogen is increased when inflammation is 
increased and has negative effects by increasing the blood clotting cascade (4, 17, 60).  
Fibrinogen increases platelet aggregation, increases plasma viscosity, and promotes fibrin 
formation (60). Increases in fibrinogen are correlated with obesity, age, smoking, diabetes 
mellitus and total cholesterol increases (60).  
 Many studies report that increases in atherosclerosis risk factors are associated with  
increased circulatory levels of inflammatory proteins including sVCAM-1, sICAM-1, sP-
selectin, and Fibrinogen (5) and can increase GDF-15 (41). These risk factors include 
obesity, smoking, diabetes, cholesterol, triglycerides, and shear stress (the frictional force of 
blood that acts against the endothelium) (5, 9, 18, 36).  However, studies have also reported 
that decreases in risk factors are associated with decreases in inflammatory proteins (5) and 
higher high density lipoprotein levels are associated with lower sVCAM-1 and sICAM-1 
(36). ADAMTS 13 determines atherosclerosis risk factors differently than other biomarkers 
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where decreased a level of ADAMTS 13 is correlated with increases in atherosclerotic risk 
(8). Each biomarker reflects a different biological process; however, each can be used to 
gauge a person’s risk for atherosclerosis.  
Conclusion  
 Atherosclerosis and cardiovascular disease risk is increased during post-menopause 
due to a decrease in both estrogen and vasodilation. Previous research has demonstrated the 
efficacy of daily watermelon consumption to increase the bioavailability of L-citrulline to 
increase the fasting plasma level of L-arginine, thus increasing NO via eNOS and eNOS 
cofactors. This can increase vasodilation and may decrease inflammation associated with the 
risk for atherosclerosis. Previous research has also demonstrated that the selected 
inflammation biomarkers can be used to gauge a person’s risk for atherosclerosis. This study 
tested the hypothesis that sICAM-1, sVCAM-1, sP-selectin, GDF-15, and fibrinogen plasma 
concentrations will decrease, and ADAMTS 13 plasma concentrations will increase after a 
six-week watermelon supplementation in overweight post-menopausal women.  Therefore, 
the purpose of this study was to determine the degree to which six select markers of 
atherosclerotic risk where affected by a six-week watermelon consumption intervention in 
overweight post-menopausal women in a community setting.  
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Methods 
Subjects 
         Sixty overweight (BMI ≥25kg/m
2
) post-menopausal women with ages ranging 
between 50-75 years were recruited. After completing a voluntary informed consent form, 
subjects were required to complete a medical health questionnaire; both forms were approved 
by Appalachian State University’s Institutional Review Board (14-0092). A medical health 
questionnaire was used to verify medical history and lifestyle habits of each subject and was 
compared to the exclusion criteria. Subjects were nonsmokers with no diagnosed history of 
chronic diseases including: coronary heart disease, stroke, cancer, type 1 or 2 diabetes 
mellitus, or rheumatoid arthritis.  Subjects that did not meet the inclusion criteria were not 
enrolled in the study. 
Experimental Design  
         The study consisted of two visits: pre- and post-study, six weeks apart at Appalachian 
State University’s Vascular Biology and Autonomic Studies Laboratory.  Each subject 
completed an overnight fast prior to the pre- and post-visits. Overnight fast included no food 
or beverage, other than water, nine or more hours prior to the visits. During both visits, 
height, weight, and percentage of body fat were measured in addition to a blood sample 
being taken.  Blood samples, ~40mL, and were obtained by a trained phlebotomist from the 
antecubital vein of each subject while the subject was in a seated position. Blood samples 
were then centrifuged, the plasma was aliquotted, and stored at -80
ₒ
C until further analysis.  
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During the pre-study visit, the subjects were randomly assigned either the control (no 
intervention) group or the watermelon treatment group.  Each group was required to maintain 
their normal diet and physical activity level, and were not allowed to make any formal 
attempt to lose weight or take any weight-loss medications throughout the six-week period. 
The watermelon group consumed 710 mL (2.27 grams of L-citrulline/L-arginine) of 
watermelon puree per day (between breakfast and dinner time), while the control group 
consumed no watermelon. 
Watermelon Supplementation 
Millionaire variety seedless Sunripe watermelons (Falls Church, VA, USA) were 
used to make the watermelon puree, and were provided by a pilot plant at the U.S. 
Department of Agriculture Citrus and Subtropical Products Laboratory (Winterhaven, FL, 
USA). Watermelon was cold pressured pasteurized and then analyzed for citrulline and 
arginine concentration (Dr. Penelope Perkins-Veazie – Plants for Human Health Institute, 
North Carolina State University). 
Watermelon puree was held at -20
ₒ
C before use. Subjects were instructed to thaw 
each bottle of watermelon puree before consumption by running the bottle under hot water. 
Each 710 mL. of watermelon puree provided 1.88 grams of L-citrulline and 0.39 grams of L-
arginine equaling 2.27 grams L-citrulline/L-arginine per day.  
Analysis of Blood  
 After the pre- and post-study blood samples were collected, the blood samples were 
centrifuged for 10 minutes at 1000 RCF and 4°C. The plasma was aliquotted and stored at -
17 
 
 
80
°
C until analysis. After the study was completed, all of the plasma samples were analyzed 
for the select cardiovascular disease biomarkers. Commercial bead-based multiplex assay 
kits were used to measure the plasma concentration of the following cardiovascular disease 
markers: ADAMTS 13, GDF-15, sVCAM-1, sICAM-1, sP-Selectin, and fibrinogen 
(MILLIPLEX® Map Kit – Human Cardiovascular Disease Magnetic Bead Kit Panel 2 and 
Panel 3; Millipore, Billerica, MA). Analysis of the cardiovascular disease markers was 
conducted according to the manufacturer’s specifications using the MAGPIX instrument 
and xPONENT analysis software (Luminex, Austin, TX). 
During the analysis process, plasma samples were diluted according to the 
manufacturer’s specifications, i.e., 1:100 with assay buffer for Panel 2 (ADAMTS 13, GDF-
15, sVCAM-1, sICAM-1, and sP-Selectin), and diluted 1:40,000 with assay buffer for Panel 
3 (fibrinogen). Seven standards were utilized to create a standard curve and two quality 
controls were utilized for each analyte. Diluted plasma samples, controls, and standards were 
added, in duplicate, across four 96-well plates. Pre- and post-study plasma samples from each 
individual were analyzed on the same plate.  
Statistics  
All data are expressed as mean ± SE. The biomarker data were analyzed using a 2 
(condition) × 2 (time) repeated-measures ANOVA, between-subject design. When significant 
interaction effects were found (p ≤ 0.05), changes were compared using two-tailed t-tests 
with significance set after Bonferroni adjustment at p ≤ 0.0125. A Cohen’s d was used to find 
the effect size of significant interactions by taking the difference between the two means and 
dividing it by the standard deviation (12).  
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Results 
Subject Characteristics  
A total of 51 subjects volunteered and completed all aspects of this study; however, 6 
subjects had a fasting blood glucose >125mg/dL at the pre-study measurement and were 
excluded from analyses. Subject’s age, body mass, body mass index (BMI), and percentage 
of body fat were compared pre- and post-intervention (Table 1).  Significant differences (p ≤ 
0.05) over time occurred in the percent body fat and in the body mass.  
Table 1 Subject Characteristics 
 Pre-Study Post-Study  Time; interaction 
effects, P-Value
a
 
Age    
 CT 60.1 ± 1.6  
WM  59.5 ± 1.0  
   
Mass (kg)   
CT 82.6 ± 3.3 82.7 ± 3.3 0.048; 0.297 
WM 84.2 ± 3.4 84.8 ± 3.4
 
 
    
BMI (kg/m
2
)    
 CT 30.3 ± 1.4 30.4 ± 1.1 0.285; 0.351 
WM 29.9 ± 1.2   31.1 ± 0.92    
    
Body Fat %    
CT 42.6 ± 1.1 43.3 ± 1.2 0.007; 0.259 
WM  42.9 ± 0.95 43.2 ± 1.0  
Notes: All data are means ± SE.
 a
The first P-value represents the overall time effect; the 
second P-value represents the condition (control vs. watermelon) × time (2 time points) 
interaction effects. CT = Control, WM = Watermelon 
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L-Arginine and L-Citrulline  
 Pre- and post-study L-arginine and L-citrulline plasma concentrations were compared 
(Table 2). The pattern of change in the plasma concentration of L-arginine was significantly 
different between groups (p = 0.022). Post-hoc analysis revealed a significant time effect (p = 
0.005) within the watermelon group, i.e., there was a significant 8.4% increase in the plasma 
L-arginine concentration that occurred between the pre-watermelon and post-watermelon 
treatment period. However, the effect size was small (Cohen’s d = -0.3486). The plasma L-
arginine concentration did not change in the control group (p > 0.05).  The pattern of change 
in the plasma L-citrulline concentration did not differ (p > 0.05) between the control and the 
watermelon group.  
Table 2. L-arginine and L-citrulline Pre- and Post-Study Plasma Concentrations 
 Pre-Study Post-Study  Time; interaction 
effects, P-Value
a
 
L-arginine    
CT 113 ± 5.9 111 ± 6.3 0.154; 0.022 
WM 98.5 ± 5.1 107 ± 5.4 *  
    
L-citrulline    
CT 45.0 ± 3.3 44.2 ± 2.9 0.881; 0.577 
WM 37.9 ± 2.9 38.4 ± 2.3  
See Table 1 for notes. * p = 0.005, within treatment group. 
Biomarkers  
 Pre- and post-study plasma concentrations for sVCAM-1, ADAMTS 13, GDF-15, 
sICAM-1, and sP-selectin were compared (Table 3). Analysis of sVCAM-1 plasma 
concentrations revealed a significant time by treatment effect (p = 0.023). Post-hoc analysis 
revealed a significant pattern of change within the watermelon group, i.e., there was a 
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significant decrease (p = 0.003) in plasma sVCAM-1 concentration that occurred between the 
pre-watermelon and post-watermelon period (Table 3); however, the effect size was small 
(Cohen’s d = 0.2388). The pattern of change in the plasma concentration of sVCAM-1 (p > 
0.05) did not differ in the control and group. The pattern of change in the plasma 
concentration of sICAM-1, ADAMTS 13, GDF-15, and sP-selectin did not differ between 
treatment groups (all, p >0.05). The plasma fibrinogen results during analysis were above 
detection limits, i.e., the analyte concentrations were higher than the highest point of the 
standard curve; therefore, fibrinogen analytes could not be accurately assessed in this 
investigation.  
Table 3 CVD Biomarker Pre- and Post-Study Plasma Concentrations 
 Pre-Study Post-Study Time ; interaction 
effects, P-Value
a
 
sVCAM-1 (ng/mL)    
CT 7.41 ± 0.40 7.46 ± 0.39 0.082; 0.023 
WM 6.86 ± 0.35   6.46 ± 0.33*  
    
ADAMTS 13 (ng/mL)    
CT 12.5 ± 0.55 12.0 ± 0.54 0.043; 0.864 
WM 12.0 ± 0.47 11.5 ± 0.46  
    
GDF-15 (pg/mL)    
CT 9.35 ± 1.00 9.36 ± 1.00 0.150; 0.147 
WM 9.74 ± 1.00 9.04 ± 1.00  
    
sICAM-1 (ng/mL)    
CT 1.70 ± 0.10 1.75 ± 0.095 0.988; 0.092 
WM 1.85 ± 0.09 1.80 ± 0.081  
    
sP-Selectin (ng/mL)    
CT 1.18 ± 0.11 1.14 ± 0.094 0.245; 0.175 
WM 1.19 ± 0.09 0.982 ± 0.08  
See Table 1 for notes. * p= 0.003, within treatment group. 
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Discussion 
The current study investigated the degree to which six select biomarkers of 
atherosclerotic risk factors were affected by the six-week watermelon consumption 
intervention in overweight post-menopausal women in a community setting. The major 
findings of this study were that fasting L-arginine plasma concentrations increased 8.4% 
through oral consumption of 0.39 grams of L-arginine and 1.88 grams of L-citrulline per day, 
and that sVCAM-1 plasma concentration significantly decreased over time in the watermelon 
group.  
Watermelon Supplementation 
The increase in the fasting plasma concentration of L-arginine over time in the 
watermelon group was due to the L-arginine and L-citrulline in the watermelon supplement. 
The fasting plasma concentration of L-citrulline was not increased. L-arginine is used 
throughout the body. 40% percent is catabolized in the intestine and 10-15% catabolized in 
the liver (13); however, extracellular L-arginine is the rate-limiting factor in nitric oxide 
production (24). L-citrulline can be released from the intestines and can bypass the liver to be 
taken up and converted into L-arginine in the kidneys (67).  The fasting plasma concentration 
of both L-arginine and L-citrulline measured in this study reflected their known metabolic 
fates.  
Collins et al. (13) supports our findings of a significant increase in the fasting L-
arginine plasma levels while no significant changes in L-citrulline fasting plasma levels can 
be found with a 2g L-citrulline/L-arginine per day watermelon supplementation. Collins et al. 
(13) concluded that fasting L-arginine plasma levels increased 11% after a 3-week 
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supplementation of 1.253g L-citrulline/L-arginine (1.025g L-citrulline/ 0.228g L-arginine), 
and fasting L-arginine plasma levels increased 22% after a 3-week supplementation of 
2.506g L-citrulline/L-arginine (2.051g L-citrulline/ 0.455g L-arginine) (13). There was a 
significant 8.4 % increase in fasting plasma L-arginine concentrations during this study. 
Collins et al. (13) controlled subject diet, while this study was in a community setting and 
diet was not strictly controlled. The community setting may account for the smaller increase 
in fasting L-arginine plasma concentration compared to the Collins et al. (13) study.  
Figueroa et al. (23) supports the employment of a six-week supplementation period. 
Figueroa et al. (23) concluded that a six-week watermelon supplementation period can have 
beneficial results on aortic blood pressure, wave reflection, and aortic and brachial pulse 
pressure. From these findings, one may predict that six-week supplementation of watermelon 
could have beneficial effects on CVD biomarkers; however, there were limited significant 
changes in the biomarkers measured in the current study. There was a smaller amount of L-
arginine and L-citrulline supplementation per day (2.27grams of L-citrulline/L-arginine) in 
this study compared to the Figueroa et al. (23) study (4grams L-citrulline/L-arginine). Thus, 
supplementation was sufficient to increase plasma L-arginine concentrations, but may not 
have been sufficient to produce beneficial results on all atherosclerotic biomarkers.  
 The control group did not make changes to their normal dietary routine. Thus, no 
changes in L-arginine and L-citrulline plasma concentrations occurred.  
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Atherosclerotic Risk Factor Biomarkers 
 While L-arginine plasma concentrations increased through watermelon 
supplementation, NO production via eNOS may have not increased due to a deficiency in 
tetrahydrobiopterin (BH4). BH4 is an essential cofactor for eNOS (10, 34, 42). GTP 
cyclohydrolase-1 is the first and rate-limiting enzyme for the synthesis of BH4, and a 
deficiency of GTP cyclohydrolase-1 in diabetic rats results in decreased BH4 synthesis, thus 
impairing NO synthases via eNOS (66). The subjects in our study were not diabetic (i.e., 
fasting blood glucose <125mg/dL); therefore, low GTP cyclohydrolase-1 activity is not 
likely. Further research will need to be conducted to examine if GTP cyclohydrolase-1 
activity is impaired in this population.  
Under oxidative stress, BH4 is oxidized into BH2 and biopterin causing a deficiency 
in BH4 (10, 34, 42). A deficiency in BH4 will cause eNOS uncoupling and generates 
superoxide rather than NO (10, 32, 34, 61). Oxidative stress will also decrease the production 
of NO (63). The uncoupling of eNOS and the decrease in NO bioavailability during oxidative 
stress can lead to endothelial dysfunction and ultimately atherosclerosis. Measures of 
oxidative stress were not made in this study; however, previous studies indicate that 
overweight post-menopausal women are under chronic oxidative stress (2). Thus, providing 
more substrate, i.e. L-arginine, may have had a limited effect on NO production. 
sVCAM-1  
 sVCAM-1 significantly decreased over time in the watermelon group in this study. 
The increase in the L-arginine concentration over the six-week supplementation period may 
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have increased NO through the L-citrulline-NO cycle. NO can limit the expression of 
sVCAM-1 (16, 43), which may account for the decrease in the plasma concentration of 
sVCAM-1 in the watermelon group. However, the small Cohen’s D effect size of this result 
may be explained by the uncoupling of eNOS. sVCAM-1 is involved in the recruitment and 
binding of leukocytes to the endothelial cell during inflammation (39). sVCAM-1 expression 
is mainly in lesions and lesion-predisposed regions, and is not expressed under healthy 
conditions (14). sVCAM-1 increases significantly during endothelial dysfunction, 
atherosclerotic conditions, and early stages of atherogenesis (14). The significant decrease in 
its plasma level may indicate that there may have been a small regression in atherosclerosis, 
endothelial dysfunction, and inflammation.  
 Previous studies have indicated that obese post-menopausal women are more at risk 
for oxidative stress (63). Oxidative stress leads to an increase in oxidation of low-density 
lipoproteins (LDL) (63), and a decrease in NO production (2). Oxidized LDL can induce the 
transcription of sVCAM-1 gene in endothelial cells (15). The significant decrease in 
sVCAM-1, with a small Cohen’s D effect size, could indicate that there was a small change 
in oxidized LDL levels and oxidative stress.  
sICAM-1 
 While sVCAM-1 and sICAM-1 are very similar in structure (14), no significant 
difference was found in the sICAM-1 plasma concentration between treatment groups. 
sVCAM-1 and sICAM-1 differ in expression timing and location (14).  sICAM-1 is present 
during basal levels (non-inflammatory state), and is expressed in endothelial cells and 
leukocytes (7). sICAM-1 expression is not limited to mature lesion regions and lesion-
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predisposed regions and may also be expressed in lesion protected regions (14). In an 
atherosclerotic state, oxidized LDL and secreted chemokines promote the expression of 
sICAM-1 (51). The six-week watermelon treatment period may not have been sufficient to 
alter oxidized-LDL or chemokine levels enough to affect sICAM-1 expression and thus 
sICAM-1 plasma concentration.  
sP-Selectin 
sP-selectin, mainly found on platelets, is stored within α-granules of platelets and 
Weibel-Palade bodies of endothelial cells, and are recruited to the endothelial cell surface 
after activation (7, 9, 52). As previously mentioned, oxidative stress increases oxidized LDL 
(63), and decreases NO production (2). Oxidized LDL stimulates sP-selectin expression on 
endothelial cells (15). While the small change in sVCAM-1 plasma concentrations suggest 
that oxidized LDL may have decreased, it might not have been sufficient to affect changes in 
sP-selectin plasma levels.  
Growth Differentiation Factor - 15 
 GDF-15 expression is increased during oxidative stress, anti-angiogenic stress, and in 
response to increased pro-inflammatory cytokines, increased oxidized LDL, mechanical 
stress (41), and in response to endothelial dysfunction (46). Each of these are risk factors for 
atherosclerosis. Lack of a significant change in GDF-15 plasma concentrations may indicate 
that there were no beneficial changes to atherosclerotic risk factors or change in endothelial 
dysfunction. GDF-15 is not exclusively an atherosclerotic risk factor, and its expression and 
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production can be increased in response to pathological or environmental stress (64). Thus, 
GDF-15 plasma concentrations may have been maintained by other mechanisms.  
ADAMTS 13 
 ADAMTS 13 decreases inflammation during atherosclerosis by cleaving highly 
active Von Willebrand Factor (VWF), and thus, making less active VWF (8, 27). VWF is 
part of the blood clotting cascade, and is involved in the recruitment and adhesion of platelets 
to activated endothelial cells at atherosclerotic sites (27). While ADAMTS 13 can bind to 
VWF during static conditions, shear stress may be needed to stretch the endothelial surface to 
expose VWF and its binding site for ADAMTS 13 (19). Further research including exercise 
and oral L-arginine and L-citrulline via watermelon puree needs to be conducted to 
determine if shear stress and L-arginine supplementation can affect ADAMTS 13 plasma 
concentrations.  
Gandhi et al. (26) examined the mechanism by which ADAMTS 13 modulates 
atherosclerosis and the breakdown of VWF in hypercholesterolemic mice. Gandhi et al. (26) 
concluded that ADAMTS 13 modulates inflammatory plaque progression through VWF-
dependent mechanism. While further research is needed to determine VWF-mechanisms, this 
may account for the lack of change in ADAMTS 13 plasma concentrations.   
Fibrinogen  
It was hypothesized that pre- and post-study fibrinogen plasma concentrations would 
decrease in the watermelon treatment group over time; however, fibrinogen results during 
analysis were above detection limits and could not be accurately measured or compared. 
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During analysis, the analyte concentrations were higher than the highest point of the standard 
curve. This did not allow the analytes to be compared to a known value for that specific 
analyte. Further research will need to be conducted to examine the effects of a six-week L-
arginine and L-citrulline supplementation on plasma fibrinogen concentrations in obese post-
menopausal women in a community setting.  
Conclusion  
 In conclusion, the six-week watermelon supplementation treatment resulted in a small 
but significant decrease in the fasting sVCAM-1 concentration, but no changes in the other 
atherosclerotic biomarkers measured. Also, the six-week watermelon supplementation 
treatment resulted in an increase in the fasting L-arginine plasma concentrations.  
Further research with exercise and oral L-arginine and L-citrulline via watermelon 
puree supplementation is required to determine if shear stress and oral L-arginine 
supplementation together can affect NO mechanisms and inflammation biomarkers in 
overweight post-menopausal women in a community setting. Shear stress has many 
beneficial properties to increase NO production, and vasodilation, including its ability to 
induce and increase BH4 levels (3). This can increase BH4 bioavailability and decrease the 
uncoupling of eNOS. By increasing BH4 bioavailability through shear stress and increasing 
plasma levels of L-arginine through consumption of watermelon puree, beneficial 
inflammation responses to decrease the risk for atherosclerosis and CVD may be obtained in 
this population. Furthermore, additional studies are needed to determine if a longer treatment 
period and/or greater dose of watermelon puree is required to decrease atherosclerotic risk in 
overweight post-menopausal women in a community setting.  
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